References
Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.
Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–85.
Bergquist JR, Ivanics T, Shubert CR, Habermann EB, Smoot RL, Kendrick ML, et al. Type of resection (Whipple vs. Distal) does not affect the national failure to provide post-resection adjuvant chemotherapy in localized pancreatic cancer. Ann Surg Oncol. 2017;24(6):1731–8.
Cady B. Basic principles in surgical oncology. Arch Surg. 1997;132(4):338–46.
Olecki E, Stahl K, Peng J, Dixon M, Gusani N, Shen C. Undertreatment of pancreatic cancer: The role of surgical pathology. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-09043-y.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Olecki, E., Gusani, N. & Shen, C. ASO Author Reflections: Undertreatment of Pancreatic Cancer After Resection: Don’t Get Fooled by Favorable Final Pathology. Ann Surg Oncol 28, 1593–1594 (2021). https://doi.org/10.1245/s10434-020-09079-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09079-0